Recent drug development efforts targeting Alzheimer's disease (AD) have failed to produce
effective disease-modifying agents for many reasons, including the substantial …

Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …

Patients with Alzheimer's disease (AD) present with both extracellular amyloid-β (Aβ)
plaques and intracellular tau-containing neurofibrillary tangles in the brain. For many years …

Glutamate is the primary excitatory neurotransmitter of the brain. Cellular homeostasis of
glutamate is of paramount importance for normal brain function and relies on an intricate …

Alzheimer's disease is a rather complex neurodegenerative disease, which is attributed to a
combination of multiple factors. Among the many pathological pathways, synaptic …

Astrocytes contribute to the complex cellular pathology of Alzheimer's disease (AD).
Neurons and astrocytes function in close collaboration through neurotransmitter recycling …

2-Deoxy-2-[18F] fluoro-d-glucose positron emission tomography (FDG-PET) is widely used
to study cerebral glucose metabolism. Here, we investigated whether the FDG-PET signal is …

Dementia is a rapidly rising global health crisis that silently disables families and ends lives
and livelihoods around the world. To date, however, no early biomarkers or effective …

Tau aggregation in neurofibrillary tangles (NFTs) is closely associated with
neurodegeneration and cognitive decline in Alzheimer's disease (AD). However, the …

The entorhinal cortex (EC) is the brain region that often exhibits the earliest histological
alterations in Alzheimer's disease (AD), including the formation of neurofibrillary tangles and …